Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hanall Biopharma Co., Ltd. (009420.KS)
KRW55,600.00
-3,100.00 (-5.28%)
KR KSC Healthcare Medical - Pharmaceuticals
Address
43, Sangseodang 1-gil 4386
Daejeon, KR
Daejeon, KR
CEO
Su-Jin Park
Website
hanall.co.kr
IPO
2000-01-04
ISIN KR7009420001
Description
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW55,600.00
-3,100.00 (-5.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
548.1K
Beta
0.79
Float Shares
33.47M
Free Float %
65.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +16.17% | +26.26% | +1.30% | +33.55% | +48.10% | +143.19% | +190.70% | +183.45% | +268.73% | +12,403.34% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
55,600.00
DCF (Levered)
2,623.51
-95.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
24.31
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +7.4%+11.7% ★ Q1'26: +10.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +24.4%-213.4% Q1'26: +235.5% (vs Q1'25)
-
FCF margin Drug Manufacturers - Specialty & Generic: +39.1%-5.2% Q1'26: +4.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +12.5%-1.0% Q1'26: +2.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +7.4%-0.9% Q1'26: +1.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.8% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Drug Manufacturers - Specialty & Generic: -0.04×16.75× ★ Q1'26: 6.61× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
80.02B
est: 85.00B (-5.9%)
|
82.88B
est: 85.00B (-2.5%)
|
91.84B
est: 92.20B (-0.4%)
|
108.45B
est: 108.13B (+0.3%)
|
88.60B
est: 88.80B (-0.2%)
|
101.59B
est: 101.90B (-0.3%)
|
110.00B
est: 112.70B (-2.4%)
|
134.91B
est: 136.96B (-1.5%)
|
138.94B
est: 141.60B (-1.9%)
|
155.18B
est: 151.63B (+2.3%)
|
166.40B
160.68B – 170.35B
+9.7% YoY
|
184.83B
168.98B – 202.56B
+11.1% YoY
|
198.00B
185.84B – 210.21B
+7.1% YoY
|
289.00B
271.25B – 306.83B
+46.0% YoY
|
| EBITDA |
-1.83B
est: 8.18B (-122.3%)
|
2.52B
est: 8.18B (-69.2%)
|
7.46B
est: 8.88B (-15.9%)
|
20.18B
est: 10.41B (+93.9%)
|
22.14B
est: 8.55B (+158.9%)
|
11.45B
est: 9.81B (+16.7%)
|
5.05B
est: 10.85B (-53.5%)
|
6.58B
est: 13.19B (-50.1%)
|
3.35B
est: 6.91B (-51.5%)
|
1.94B
est: 7.40B (-73.8%)
|
8.12B
7.84B – 8.31B
+9.7% YoY
|
9.02B
8.25B – 9.89B
+11.1% YoY
|
9.66B
9.07B – 10.26B
+7.1% YoY
|
14.11B
13.24B – 14.98B
+46.0% YoY
|
| EBIT |
-4.14B
est: 5.91B (-170.1%)
|
285.40M
est: 5.91B (-95.2%)
|
5.47B
est: 6.41B (-14.6%)
|
17.47B
est: 7.52B (+132.4%)
|
19.24B
est: 6.17B (+211.7%)
|
8.73B
est: 7.08B (+23.2%)
|
2.00B
est: 7.84B (-74.5%)
|
3.34B
est: 9.52B (-65.0%)
|
230.47M
est: 3.40B (-93.2%)
|
-1.61B
est: 3.64B (-144.3%)
|
4.00B
3.86B – 4.09B
+9.7% YoY
|
4.44B
4.06B – 4.86B
+11.1% YoY
|
4.75B
4.46B – 5.05B
+7.1% YoY
|
6.94B
6.51B – 7.37B
+46.0% YoY
|
| Net Income |
-7.08B
est: 507.14M (-1,495.5%)
|
2.03B
est: 507.14M (+299.5%)
|
3.30B
est: 4.53B (-27.1%)
|
19.17B
est: 20.18B (-5.0%)
|
19.76B
est: 17.19B (+15.0%)
|
8.90B
est: 14.15B (-37.1%)
|
251.47M
est: 6.09B (-95.9%)
|
3.51B
est: 7.45B (-52.9%)
|
-1.80B
est: 6.71B (-126.9%)
|
-5.56B
est: 6.85B (-181.1%)
|
9.01B
-1.34B – 24.17B
+31.5% YoY
|
764.00M
4.74M – 2.32B
-91.5% YoY
|
3.89B
3.58B – 4.20B
+408.7% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
13.12B
est: 20.08B (-34.7%)
|
10.06B
est: 20.08B (-49.9%)
|
13.82B
est: 21.78B (-36.5%)
|
16.82B
est: 25.54B (-34.2%)
|
17.38B
est: 20.98B (-17.1%)
|
20.52B
est: 24.07B (-14.7%)
|
23.24B
est: 26.62B (-12.7%)
|
48.04B
est: 32.35B (+48.5%)
|
29.95B
est: 34.88B (-14.1%)
|
38.27B
est: 37.35B (+2.5%)
|
40.99B
39.58B – 41.96B
+9.7% YoY
|
45.53B
41.62B – 49.89B
+11.1% YoY
|
48.77B
45.77B – 51.78B
+7.1% YoY
|
71.18B
66.81B – 75.57B
+46.0% YoY
|
| EPS |
-159.00
est: 10.00 (-1,690.0%)
|
40.00
est: 10.00 (+300.0%)
|
64.48
est: 89.25 (-27.8%)
|
374.67
est: 398.00 (-5.9%)
|
386.19
est: 339.00 (+13.9%)
|
173.74
est: 279.00 (-37.7%)
|
4.95
est: 120.00 (-95.9%)
|
69.21
est: 146.86 (-52.9%)
|
-35.59
est: 134.67 (-126.4%)
|
-111.55
est: 137.50 (-181.1%)
|
180.75
-26.85 – 485.14
+31.5% YoY
|
15.33
0.10 – 46.50
-91.5% YoY
|
78.00
71.77 – 84.25
+408.7% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-10 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
5.99B
OE per share TTM
115.12
Owner's Yield
0.18%
Maintenance CapEx ratio
30.09%
Maint CapEx / Avg PPE
14.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-5.12M
Shares Outstanding
50.79M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher W. Slavinsky | Chief Business Development & Legal Officer | — | male |
| Hye Kyung Ahn | Head of Research Division | — | female |
| Jae-Seung Yoon | C.V.O | — | male |
| Nam-Yong Cho | Senior Executive Director of Sales & Marketing and Senior Managing Director | — | — |
| Sean Jeong | President, Co-CEO & Director | — | male |
| SeongUn Kim | Head of Business Management Division | — | male |
| Su-Jin Park | Co-CEO, VP & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 009420.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
